This Study Seeks to Prevent Cancer By Targeting Genetic Risk For Ovarian Cancer

This Study Seeks to Prevent Cancer By Targeting Genetic Risk For Ovarian Cancer

Researchers in gynecologic oncology have begun testing a promising surgery for premenopausal women at high genetic risk for ovarian cancer that avoids early menopause and may prevent these malignancies from developing. Studies have shown that most ovarian cancers actually begin to grow from cancer cells that developed in the fallopian tubes. This trial is testing … Read more

This Scientist Focuses On How Cells Record Trauma

This Scientist Focuses On How Cells Record Trauma

Barbara Engelhardt, PhD, builds machine-learning models and statistical tools to make use of data (scientific experiments, longitudinal studies, clinical trials, and hospital records) and find ways to better understand, and even prevent, disease. She is now joining Gladstone Institutes as a senior investigator. Engelhardt is also a full professor at Princeton University, on leave this … Read more

NIH To Fund $185 Million For Research Into Human Genome Functions

NIH To Fund $185 Million For Research Into Human Genome Functions

The National Institutes of Health (NIH) is providing approximately $185 million over five years to the Impact of Genomic Variation on Function (IGVF) consortium, initiated and funded by NIH’s National Human Genome Research Institute (NHGRI). NHGRI will fund 25 awards across 30 U.S. research sites. IGVF consortium investigators will work to understand how genomic variation … Read more

How CAR T Cells Are Engineered To Treat Cancers

How CAR T Cells Are Engineered To Treat Cancers

For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last two decades, targeted therapies like imatinib (Gleevec®)  and trastuzumab (Herceptin®) —drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells—have also cemented themselves as standard treatments for many cancers. But over the past several years, immunotherapy—therapies that enlist and … Read more

WARF Dive: Synthetic Ligands Capable of Strongly Inhibiting or Inducing Quorum Sensing in Bacteria

WARF Dive: Synthetic Ligands Capable of Strongly Inhibiting or Inducing Quorum Sensing in Bacteria

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a powerful new class of chemical probes that are capable of strongly inhibiting or inducing quorum sensing. Quorum sensing is a process used by some bacteria to coordinate behavior based on local population density. To communicate, bacteria release signaling molecules, including low … Read more